Axa S.A. Biomea Fusion, Inc. Transaction History

Axa S.A.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$3.0 - $12.03 $351,000 - $1.41 Million	-117,000 Closed	0 $0
Q1 2022 Feb 14, 2023	BUY	$4.39 - $9.03 $513,629 - $1.06 Million	117,000 New	117,000 $521,000
Q1 2022 May 13, 2022	BUY	$4.39 - $9.03 $8 - $18	2 Added 0.0%	117,000 $522,000
Q4 2021 Feb 14, 2022	BUY	$7.22 - $12.72 $10,093 - $17,782	1,398 Added 1.21%	116,998 $872,000
Q3 2021 Nov 15, 2021	BUY	$10.0 - $15.99 $42,500 - $67,957	4,250 Added 3.82%	115,600 $1.38 Million
Q2 2021 Aug 13, 2021	BUY	$13.65 - $20.93 $1.52 Million - $2.33 Million	111,350 New	111,350 $1.74 Million

104

17.8M

1.68M

410K

Ticker BMEA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 29,290,600
Market Cap $114M
Description
Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in onc...

Get notified when there are updates to the investment portfolio of Axa S.A., based on Form 13F filings with the SEC.

Stay updated on Axa S.A. with notifications on news.